Phytoestrogens in Botanical Dietary Supplements: Implications for Cancer

Integrative Cancer Therapies

Volumn 2, Issue 2, 2003, Pages 120-138

  Piersen, Colleen E ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b M/C 877 ^*  (United States)

Author keywords

Antioxidant; Botanical; Breast cancer; Chemopreventive; Estrogen receptor; Herb; Isoflavone; Menopause; Phytoestrogen

Indexed keywords

4' METHOXYCOUMESTROL; ANGELICA SINENSIS EXTRACT; ANTIOXIDANT; BICHANIN A; CHEMOPREVENTIVE AGENT; CIMICIFUGA RACEMOSA EXTRACT; COUMESTROL; DAIDZEIN; DAIDZIN; ESTROGEN; ESTROGEN RECEPTOR; GENISTEIN; GENISTIN; GLYCETIN; GLYCITEIN; GLYCYRRHIZA GLABRA EXTRACT; HERBACEOUS AGENT; HUMULUS LUPULUS EXTRACT; ISOFLAVONE; LARICIRESINOL; MATAIRESINOL; PHYTOESTROGEN; PINORESINOL; PLANT EXTRACT; PRUNETIN; RED CLOVER EXTRACT; SECOISOLARICIRESINOL; SISSOTRIN; SYRINGARESINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DRUG MECHANISM; ESTROGEN ACTIVITY; EXPERIMENTAL MODEL; HORMONE DEPENDENCE; MENOPAUSE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; ISOFLAVONES; NEOPLASMS, HORMONE-DEPENDENT; PHYTOESTROGENS; PHYTOTHERAPY; PLANT PREPARATIONS; PROGNOSIS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 0142210160     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735403002002004     Document Type: Review

References (190)

1. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002;346(5):340-352.
2. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1569-1575.
3. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001;135(4):262-268.
4. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer. A systematic review. Cancer. 1998;83(4):777-782.
5. Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol. 2002;3(6):364-373.
6. Liu J, Burdette J, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem. 2001;49(5):2472-2479.
7. Johnson BM, Nikolic D, van Breemen RB. Applications of pulsed ultrafiltration mass spectrometry. Mass Spectrometry Rev. 2002;21(2):76-86.
8. Diel P, Schulz T, Smolnikar K, Strunck E, Vollmer G, Michna H. Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: estrogenicity profiles and uterotropic activity. J Steroid Biochem Mol Biol. 2000;73(1-2):1-10.
9. Pisha E, Pezzuto JM. Cell-based assay for the determination of estrogenic and anti-estrogenic activities. Methods Cell Sci. 1997;19:37-43.
10. Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Perspect. 1995;103(Suppl 7):113-122.
11. Schmitt E, Dekant W, Stopper H. Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro. 2001;15(4-5):433-439.
12. Metzger D, White JH, Chambon P. The human oestrogen receptor functions in yeast. Nature. 1988;314(6177):31-36.
13. Pham TA, Hwung YP, Santiso-Mere D, McDonnell DP, O'Malley BW. Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast. Mol Endocrinol. 1992;6(7):1043-1050.
14. Li Y, Liang W, Nikolic D, et al. Transport and metabolism of isoflavones in an extract of Trifolium pratense (red clover) by the human intestinal cell line Caco-2. Abstract presented at 50th ASMS Conference on Mass Spectrometry and Allied Topics; June 2-6, 2002; Orlando, Fla.
15. Nikolic D, Li Y, Farnsworth NR, van Breemen RB. Transport and metabolism of 8-prenylnaringenin, a potent phytoestrogen from hops (Humulus lupulus) by human intestinal Caco-2 cells and hepatocytes. Abstract presented at 50th ASMS Conference on Mass Spectrometry and Allied Topics; June 2-6, 2002; Orlando, Fla.
16. Moule GR, Braden AWH, Lamond DR. The significance of oestrogens in pasture plants in relation to animal production. Anim Breed Abstr. 1963;32:139-157.
17. Bennetts HW, Underwood EJ, Shier FL. A specific breeding problem of sheep on subterranean clover pastures in Western Australia. Aust Vet J. 1946;22:2-12.
18. Diel P, Schmidt S, Vollmer G. In vivo test systems for the quantitative and qualitative analysis of the biological activity of phytoestrogens. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;777(1-2):191-202.
19. Degen GH, Janning P, Diel P, Bolt HM. Estrogenic isoflavones in rodent diets. Toxicol Lett. 2002;128(1-3):145-157.
20. Pan Y, Anthony M, Watson S, Clarkson TB. Soy phytoestrogens improve radial arm maze performance in ovariectomized retired breeder rats and do not attenuate benefits of 17beta-estradiol treatment. Menopause. 2000;7(4):230-235.
21. Lephart ED, West TW, Weber KS, et al. Neurobehavioral effects of dietary soy phytoestrogens. Neurotoxicol Teratol. 2002;24(1):5-16.
22. Constantinou AI, Lantvit D, Hawthorne M, Xu X, van Breemen RB, Pezzuto JM. Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr Cancer 2001;41(1-2):75-81.
23. Fabian CJ, Kimler BF. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Ann N Y Acad Sci. 2001;952:44-59.
24. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999;84(11):4017-4024.
25. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132(12):3577-3584.
26. Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer MS. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(6):581-586.
27. Martini MC, Dancisak BB, Haggans CJ, Thomas W, Slavin JL. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer: 1999;34(2):133-139.
28. Collins BM, McLachlan JA, Arnold SF. The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids. 1997;62(4):365-372.
29. Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med. 1998;217(3):369-378.
30. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139(10):4252-4263.
31. Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res. 1997;26(1):63-70.
32. Chin-Dusting JP, Fisher LJ, Lewis TV, Piekarska A, Nestel PJ, Husband A. The vascular activity of some isoflavone metabolites: implications for a cardioprotective role. Br J Pharmacol. 2001;133(4):595-605.
33. Huang RQ, Fang MJ, Dillon GH. The tyrosine kinase inhibitor genistein directly inhibits GABAA receptors. Brain Res Mol Brain Res. 1999;67(1):177-183.
34. Ji XD, Melman N,Jacobson KA. Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996;39(3):781-788.
35. Jacobson KA, Moro S, Manthey JA, West PL, Ji XD. Interactions of flavones and other phytochemicals with adenosine receptors. Adv Exp Med Biol. 2002;505:163-171.
36. Dixon-Shanies D, Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol Rep. 1999;6(6):1383-1387.
37. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res. 1993;53(23):5815-5821.
38. Saloniemi H, Wahala K, Nykanen-Kurki P, Kallela K, Saastamoinen I. Phytoestrogen content and estrogenic effect of legume fodder. Proc Soc Exp Biol Med. 1995;208(1):13-17.
39. Burdette J, Liu J, Lantvit D, et al. Trifolium pratense (red clover) exhibits estrogenic effects in vivo in ovariectomized Sprague-Dawley rats. J Nutr. 2002;132(1):27-30.
40. Diel P, Smolnikar K, Schulz T, Laudenbach-Leschowski U, Michna H, Vollmer G. Phytoestrogens and carcinogenesis-differential effects of genistein in experimental models of normal and malignant rat endometrium. Hum Reprod. 2001;16(5):997-1006.
41. Anthony MS, Clarkson TB, Hughes CL Jr, Morgan TM, Burke GL. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr. 1996;126(1):43-50.
42. Balmir F, Staack R, Jeffrey E, Jimenez MD, Wang L, Potter SM. An extract of soy flour influences serum cholesterol and thyroid hormones in rats and hamsters. J Nutr. 1996;126(12):3046-3053.
43. Arjmandi BH, Birnbaum R, Goyal NV, et al. Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr. 1998;68(6 Suppl):1364S-1368S.
44. Ishida H, Uesugi T, Hirai K, et al. Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet. Biol Pharm Bull. 1998;21(1):62-66.
45. Picherit C, Coxam V, Bennetau-Pelissero C, et al. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr. 2000;130(7):1675-1681.
46. Baber RJ, Templeman C, Morton T, Kelly GE, West L. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric. 1999;2:85-92.
47. Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric. 1999;2:79-84.
48. van de Weijer P, Barentsen R. Isoflavones from red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas. 2002;42(3):187.
49. Nachtigall LE, Nachtigall LB. The effects of isoflavones derived from red clover on vasomotor symptoms and endometrial thickness. Paper presented at 9th International Menopause Society World Congress on the Menopause, 1999; Yokohama, Japan.
50. Jeri AR. The use of an isoflavone supplement to relieve hot flushes. The Female Patient. 2002;28:8.
51. Hale GE, Hughes CL, Robboy SJ, Agarwal SK, Bievre M. A double-blind randomized study on the effects of red clover isoflavones on the endometrium. Menopause. 2001;8(5):338-346.
52. Ingram DM, Hickling C, West L, Mahe LJ, Dunbar PM. A double-blind randomized controlled trial of isoflavones in the treatment of cyclical mastalgia. The Breast. 2002;11:170-174.
53. Kontostolis E, Stefanidis K, Navrozoglou I, Lolis D. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. Gynecol Endocrinol. 1997;11(6):393-397.
54. Nestel PJ, Pomeroy S, Kay S, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab. 1999;84(3):895-898.
55. Samman S, Lyons Wall PM, Chan GS, Smith SJ, Petocz P. The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in premenopausal women. Atherosclerosis. 1999;147(2):277-283.
56. Howes JB, Sullivan D, Lai N, et al. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of postmenopausal women with mild to moderate hypercholesterolemia. Atherosclerosis. 2002;152:143-147.
57. Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol. 1997;17(12):3392-3398.
58. Atkinson C, Compston JE, Robins SP, Bingham SA. The effects of isoflavone phytoestrogens on bone: preliminary results from a large randomised controlled trial. Paper presented at 82nd Annual Meeting of the Endocrine Society; June 21-24, 2000; Stamford, Conn.
59. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery M-L, Moreton T The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause. 2001;8(4):259-265.
60. Jarred RA, Keikha M, Dowling C, et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1689-1696.
61. Lewis JG, Morris JC, Clark BM, Elder PA. The effect of isoflavone extract ingestion, as Trinovin, on plasma steroids in normal men. Steroids. 2002;67(1):25-29.
62. Mahady GB, Fong HHS, Farnsworth NR. WHO Monographs on Selected Medicinal Plants. Vol II. Genexa, Switzerland: World Health Organization, Traditional Medicine Programme; 2002.
63. Brinker F. Review of Macrotys (black cohosh). Eclectic Med J. 1996;11(1):2-4.
64. Blumenthal M, ed. Herbal Medicine: Expanded Commission E Monographs. 1st ed. Newton, Mass: Integrative Medicine Communications; 2000.
65. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause. 2003;10(1):58-64.
66. Jarry H, Harnischfeger G, Düker E. The endocrine effects of constituents of Cimicifuga racemosa: 2. In vitro binding of constituents to estrogen receptors. Planta Med. 1985(4):316-319.
67. Jarry H, Harnischfeger G. Endocrine effects of constituents of Cimicifuga racemosa: 1. The effect on serum levels of pituitary hormones in ovariectomized rats. Planta Med. 1985(1):46-49.
68. Düker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats. Planta Med. 1991;57(5):420-424.
69. Struck D, Tegtmeier M, Harnischfeger G. Flavones in extracts of Cimicifuga racemosa. Planeta Medica. 1997;63:289-290.
70. Fabricant DS, Li W, Chen S-N, et al. Geographical and diurnal variation of chemical constituents of Cimicifuga racemosa (L.) Nutt. Paper presented at 2001 Interim Meeting of the American Society of Pharmacognosy & Council for Responsible Nutrition; November 8-11, 2001; Asilomar, Calif.
71. Onorato J, Henion JD. Evaluation of triterpene glycoside estrogenic activity using LC/MS and immunoaffinity extraction. Anal Chem. 2001;73(19):4704-4710.
72. Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause. 2002;9(2):145-150.
73. Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat. 2002;76(1):1-10.
74. Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol. 2002;80(1):125-130.
75. Liu Z, Yang Z, Zhu M, Huo J. Estrogenicity of black cohosh (Cimicifuga racemosa) and its effect on estrogen receptor level in human breast cancer MCF-7 cells. Wei Sheng Yan Jiu. 2001;30(2):77-80.
76. Liu ZP, Yu B, Huo JS, Lu CQ, Chen MS, Chen JS. Estrogenic effects of Cimicifuga racemosa (black cohosh) in mice and on estrogen receptors in MCF-7 cells. J Med Food. 2001;4(3):171-178.
77. Bruggisser R, von Daeniken K, Jundt G, Schaffner W, Tullberg-Reinert H. Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med. 2002;68(5):445-448.
78. Kruse SO, Lohning A, Pauli GF, Winterhoff H, Nahrstedt A. Fukiic and piscidic acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity of fukinolic acid. Planta Med. 1999;65(8):763-764.
79. Foldes J. The actions of an extract of Cimicifuga racemosa. Arneimittelforschung. 1959;13:623-624.
80. Eagon CL, Elm MS, Teepe AG, Eagon PK. Medicinal botanicals: estrogenicity in rat uterus and liver. Paper presented at American Association for Cancer Research; March 1997.
81. Einer-Jensen N, Zhao J, Andersen KP, Krsitoffersen K. Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. Maturitas. 1996;25:149-153.
82. Freudenstein J, Dasenbrock C, Nißlein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract. Cancer Res. 2002;62(12):3448-3452.
83. Burdette J, Liu J, Chen S-N, et al. Abstract #103214. Abstract presented at 94th Annual Meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Canada.
84. Borrelli F, Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol. 2002;58(4):235-241.
85. Mahady GB, Fabricant DS, Chadwick LR, Dietz B. Black cohosh: an alternative therapy for menopause? Nutr Clin Care. 2002;5(6):283-289.
86. Stoll W. Phytopharmakon influences atrophic vaginal epithelium: double-blind study - Cimicifuga vs. estrogenic substances. Therapueticum. 1987;1:23-31.
87. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19(10):2739-2745.
88. Liske E, Hanggi W, Henneicke-von Zepelin HH, Boblitz N, Wustenberg P, Rahlfs VW. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med. 2002;11(2):163-174.
89. Warnecke G. Influencing menopausal symptoms with a phytotherapeutic agent. Die Medizinische Welt. 1985;36:871-874.
90. Lehmann-Willenbrock E, Riedel H-H. Clinical and endocrinologic examinations concerning therapy of climacteric symptoms following hysterectomy with remaining ovaries. Zentralbl Gynakol. 1988;110:611-618.
91. Popp M, Schenk R, Abel G. Cultivation of Cimicifuga racemosa (L.) Nuttal and quality of CR extract BNO 1055. Maturitas. 2003;44 Suppl 1:S1-7.
92. Jarry H, Metten M, Spengler B, Christoffel V, Wuttke W. In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas. 2003;44 Suppl 1:S31-S38.
93. Seidlová-Wuttke D, Jarry H, Becker T, Christoffel V, Wuttke W. Pharmacology of Cimicifuga racemosa extract BNO 1055 in rats: bone, fat and uterus. Maturitas. 2003;44 Suppl 1:S39-S50.
94. Winterhoff H, Spengler B, Christoffel V, Butterweck V, Lohning A. Cimicifuga extract BNO 1055: reduction of hot flushes and hints on antidepressant activity. Maturitas. 2003;44 Suppl 1:S51-S58.
95. Wuttke W, Seidlová-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas. 2003;44 Suppl 1:S67-S77.
96. Hernández Muñoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas. 2003;44 Suppl 1:S59-S65.
97. Wuttke W, Jarry H, Becker T, et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? Maturitas. 2003;44 Suppl 1:S9-S20.
98. Burdette JE, Chen SN, Lu ZZ, et al. Black cohosh (Cimicifuga racemosa L.) protects against menadione-induced DNA damage through scavenging of reactive oxygen species: bioassay-directed isolation and characterization of active principles. J Agric Food Chem. 2002;50(24):7022-7028.
99. Milligan SR, Kalita JC, Pocock V, et al. The endocrine activities of 8-prenylnaringenin and related hop (Humulus lupulus L.) flavonoids. J Clin Endocrinol Metab. 2000;85(12):4912-4915.
100. Burdette J, Liu J, Chadwick LR, et al. Evaluation of Humulus lupulus (hops) extracts for estrogenic properties. Abstract presented at 222nd National Meeting of the American Chemical Society; August 26-30, 2001; Chicago, 111.
101. Milligan S, Kalita J, Pocock V, et al. Oestrogenic activity of the hop phyto-oestrogen, 8-prenylnaringenin. Reproduction. 2002;123(2):235-242.
102. Koch W, Heim G. Östrogene Homrone in Hopfen und Bier. Münch Med Wschr. 1953;95:845.
103. Zenisek A, Bednar J. Contribution to the identification of the estrogen activity of hops. Am Perfumer Arom. 1960;75:61.
104. Churý, J. Über den Phytoöstrogengehalt einiger Pflanzen. Experientia. 1960;16:194.
105. Fenselau C, Talalay P. Is oestrogenic activity present in hops? Food Cosmet Toxicol. 1973;11:597-603.
106. Tobe H, Muraki Y, Kitamura K, et al. Bone resorption inhibitors from hop extract. Biosci Biotechnol Biochem. 1997;61(1):158-159.
107. Kitaoka M, Kadokawa H, Sugano M, et al. Prenylflavonoids: a new class of non-steroidal phytoestrogen (Part 1). Isolation of 8-isopentenylnaringenin and an initial study on its structure-activity relationship. Planta Med. 1998;64(6):511-515.
108. Kitaoka M, Kadokawa H, Sugano M, et al. Prenylflavonoids: a new class of non-steroidal phytoestrogen (Part 2). Estrogenic effects of 8-isopentenylnaringenin on bone metabolism. Planta Med. 1998;64(6):516-519.
109. Tagashira M, Watanabe M, Uemitsu N. Antioxidative activity of hop bitter acids and their analogues. Biosci Biotechnol Biochem. 1995;59(4):740-742.
110. Miranda CL, Stevens JF, Helmrich A, et al. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol. 1999;37(4):271-285.
111. Miranda CL, Stevens JF, Ivanov V, et al. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J Agric Food Chem. 2000;48(9):3876-3884.
112. Miranda CL, Yang YH, Henderson MC, et al. Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo [4, 5-f]quinoline, mediated by cDNA-expressed human CYP1A2. Drug Metab Dispos. 2000;28(11):1297-1302.
113. Gerhauser C, Alt A, Heiss E, et al. Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. Mol Cancer Ther. 2002;1(11):959-969.
114. Schmitz M, Jackel M. Comparative study for assessing quality of life of patients with exogenous sleep disorders treated with a hops-valerian preparation and a benzodiazepam drug. Wien Med Wochenschrr. 1998; 148(13):291-298.
115. Baker ME, Fanestil DD. Liquorice as a regulator of steroid and prostaglandin metabolism. Lancet. 1991;337:428-429.
116. Kassir ZA. Endoscopic controlled trial of four drug regimens in the treatment of chronic duodenal ulceration. Irish Med J. 1985;78:153-156.
117. Bernardi M, D'Intino PE, Trevisani F, et al. Effects of prolonged ingestion of graded doses of licorice by healthy volunteers. Life Sci. 1994;55(11):863-872.
118. Tamir S, Eizenberg M, Somjen D, Izrael S, Vaya J. Estrogen-like activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol. 2001;78(3):291-298.
119. Maggiolini M, Statti G, Vivacqua A, et al. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J Steroid Biochem Mol Biol. 2002;82(4-5):315-322.
120. Tamir S, Eizenberg M, Somjen D, et al. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer Res. 2000;60(20):5704-5709.
121. Kumagai A, Nishino K, Shimomura A, Kin T, Yamamura Y. Effect of glycyrrhizin on estrogen action. Endocrinol Japan. 1967;14(1):34-38.
122. Wang ZY, Nixon DW. Licorice and cancer. Nutr Cancer. 2001;39(1):1-11.
123. Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr. 1999;70(3 Suppl):491S-499S.
124. Yokozawa T, Liu ZW, Chen CP. Protective effects of Glycyrrhizae radix extract and its compounds in a renal hypoxia (ischemia)-reoxygenation (reperfusion) model. Phytomedicine. 2000;6(6):439-445.
125. Vaya J, Belinky PA, Aviram M. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic Biol Med. 1997;23(2):302-313.
126. Haraguchi H, Yoshida N, Ishikawa H, Tamura Y, Mizutani K, Kinoshita T. Protection of mitochondrial functions against oxidative stresses by isoflavans from Glycyrrhiza glabra. J Pharm Pharmacol. 2000;52(2):219-223.
127. Rosenblat M, Belinky P, Vaya J, et al. Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell-mediated oxidation of low density lipoprotein. A possible role for protein kinase C. J Biol Chem. 1999;274(20):13790-13799.
128. Armanini D, Bonanni G, Palermo M. Reduction of serum testosterone in men bylicorice. N Engl J Med. 1999;341(15):1158.
129. Josephs RA, Guinn JS, Harper ML, Askari F. Liquorice consumption and salivary testosterone concentrations. Lancet. 2001;358(9293):1613-1614.
130. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339(12):785-791.
131. Sovak M, Seligson AL, Konas M, et al. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst. 2002;94(17):1275-1281.
132. Strandberg TE, Andersson S, Jarvenpaa AL, McKeigue PM. Preterm birth and licorice consumption during pregnancy. Am J Epidemiol. 2002;156(9):803-805.
133. Strandberg TE, Jarvenpaa AL, Vanhanen H, McKeigue PM. Birth outcome in relation to licorice consumption during pregnancy. Am J Epidemiol. 2001;153(11):1085-1088.
134. Liao J-F, Jan Y-M, Huang S-Y, Wang H-H, Yu L-L, Chen C-F. Evaluation of receptor binding assay on the water extracts of ten CNS-active Chinese herbal drugs. Proc Natl Sci Council, ROC. 1995;19(3):151-158.
135. Han C-Q, Pan J-X, Li C-L, Tu F. The screening of Chinese traditional drugs by biological assay and the isolation of some active components. Int J Chin Med. 1991;16(1):1-17.
136. Lu FHea. Pharmacological study of danggui (Angelica sinensis). Natl Med J China. 1954;39:670.
137. Pi XP, Effects of Angelica sinensis on the uterus. Natl Med J China. 1955;40:967.
138. Harada M, Suzuki M, Ozaki Y. Effect of Japanese angelica root and peony root on uterine contraction in the rabbit in situ. J Pharmacobiodyn. 1984;7(5):304-311.
139. Ozaki Y, Ma JP. Inhibitory effects of tetramethylpyrazine and ferulic acid on spontaneous movement of rat uterus in situ. Chem Pharm Bull (Tokyo). 1990;38(6):1620-1623.
140. Zhu DPQ. Dong Quai. Am J Chinese Med. 1987;XV(3-4):117-125.
141. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997;68(6):981-986.
142. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262(12):5592-5595.
143. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol. 1995;147(2):295-302.
144. Kellis JT Jr, Vickery LE. Inhibition of human estrogen synthetase (aromatase) by flavones. Science. 1984;225(4666):1032-1034.
145. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol. 1993;44(2):147-153.
146. Bhat KP, Pezzuto JM. Natural modulators of estrogen biosynthesis and function as chemopreventive agents. Arch Pharm Res. 2001;24(6):473-484.
147. Mousavi Y, Adlercreutz H. Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol. 1992;41(3-8):615-619.
148. Mousavi Y, Adlercreutz H. Genistein is an effective stimulator of sex hormone-binding globulin production in hepatocarcinoma human liver cancer cells and suppresses proliferation of these cells in culture. Steroids. 1993;58(7):101-304.
149. Adlercreutz H, Hockerstedt K, Bannwart C, et al. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem. 1987;27(4-6):1135-1144.
150. Kirk CJ, Harris RM, Wood DM, Waring RH, Hughes PJ. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens? Biochem Soc Trans. 2001;29(Pt 2):209-216.
151. Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, Slavin JL. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer. 1999;33(2):188-195.
152. Constantinou A, Kiguchi K, Huberman E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res. 1990;50(9):2618-2624.
153. Markovits J, Linassier C, Fosse P, et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 1989;49(18):5111-5117.
154. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA. 1993; 90(7):2690-2694.
155. Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am. J Clin Nutr 2000;71(6 Suppl):1705S-1707S; discussion 1708-1709S.
156. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects ofgenistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998;58(17):3833-3838.
157. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause. 1999;6(1):7-13.
158. Anderson JW, Johnstone BM, Cook-Newall ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276-282.
159. Merz-Demlow BE, Duncan AM, Wangen KE, et al. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am J Clin Nutr. 2000;71(6):1462-1469.
160. Vigna GB, Pansini F, Bonaccorsi G, et al. Plasma lipoproteins in soy-treated postmenopausal women: a double-blind, placebo-controlled trial. Nutr Metab Cardiovasc Dis. 2000;10(6):315-322.
161. Wangen KE, Duncan AM, Xu X, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr. 2001;73(2):225-231.
162. Lucas EA, Wild RD, Hammond LJ, et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2002;87(4):1527-1532.
163. Jenkins DJ, Kendall CW, Vidgen E, et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr. 1999;69(3):395-402.
164. van der Schouw YT, Pijpe A, Lebrun CEI, et al. Higher usual dietary intake of phytoestrogens in associated with lower aortic stiffness in postmenopausal women. Arterioscler Thromb Vasc Biol. 2002;22:1316-1322.
165. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000;72(3):844-852.
166. Greendale GA, FitzGerald G, Huang MH, et al. Dietary soy isoflavones and bone mineral density: results from the study of women's health across the nation. Am J Epidemiol. 2002;155(8):746-754.
167. Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study. J Am Coll Nutr. 2002;21(2):97-102.
168. Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenberg DM. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med. 2002;137(11):889-903.
169. Prasad KN, Cole WC, Kumar B, Che Prasad K. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev. 2002;28(2):79-91.
170. Block KI, Gyllenhaal C. Clinical corner: herb-drug interactions in cancer chemotherapy: theoretical concerns regarding drug metabolizing enzymes. Int Cancer Ther. 2002;1(1):83-89.
171. Henderson MC, Miranda CL, Stevens JF, Deinzer ML, Buhler DR. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica. 2000;30(3):235-251.
172. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 2000;7(4):273-282.
173. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
174. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Cynecol. 1982;60(5):583-586.
175. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994;12(1):155-158.
176. Loprinzi CL, Goldberg RM, O'Fallon JR, et al. Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol. 1994;151(3):634-636.
177. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059-2063.
178. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20(6):1578-1583.
179. Guttuso T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101(2):337-345.
180. Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric. 1998;1(2):124-129.
181. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol. 1998;91(1):6-11.
182. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause. 2000;7(4):236-242.
183. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause. 2000;7(2):105-111.
184. St. Germain A, Peterson CT, Robinson JG, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause. 2001;8:17-26.
185. Han KK, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol. 2002;99(3):389-394.
186. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16(2):495-500.
187. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 2002;20(6):1449-1455.
188. Chenoy R, Hussain S, Tayob Y, O'Brien PM, Moss MY, Morse PF. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ. 1994;308(6927):501-503.
189. Wiklund IK, Mattsson LA, Lindgren R, Limoni C. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int J Clin Pharmacol Res. 1999;19(3):89-99.
190. Blatt MH, Wiesbader H, Kupperman HS. Vitamin E and climacteric syndrome. Arch Int Med. 1953;91:792-796.